Drugs / EC-MPS
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 4 | NCT01033864 Comparator | Nov 2009 → Jun 2010 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00611494 Comparator | Jan 2008 → Dec 2009 | disease related to solid organ transplantation | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT00284947 Background | Jan 2006 → Dec 2008 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00229138 Background | Sep 2005 → Mar 2007 | — | Novartis Pharmaceuticals | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EC-MPS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00229138 ↗ |
| Known as | Enteric-Coated Mycophenolate Sodium | “Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients” NCT00229138 ↗1“Mycophenolate mofetil (MMF, CellCept) and Enteric-Coated Mycophenolate Sodium (EC-MPS, Myfortic)” NCT00611494 ↗ |
| Route | Oral | “1g MMF or 720mg EC-MPS p.o twice daily” NCT00284947 ↗ |